Carlos Fernandez, PharmD (@rojasfec) header
Carlos Fernandez, PharmD (@rojasfec) profile picture

Medical Advisor Nephrology/Cardiovascular Medical Affairs, Novartis Canada. Views, posts, opinions are my own, not that of my employer.

Montreal, QC
Joined November 2010
Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)Photo by Carlos Fernandez, PharmD (@rojasfec)
Carlos Fernandez, PharmD retweeted
bit.ly/4l4k1mv Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era
17
1
32
4,432
Carlos Fernandez, PharmD retweeted
Approximately 80% of all strokes are ischaemic. The underlying pathology is often multifactorial, involving interrelated arterial and cardiac conditions. Identifying the specific cause of stroke is critical for short-term and long-term care. Learn more: ow.ly/C44P50WluMQ
2
42
162
10,358
Carlos Fernandez, PharmD retweeted
☝️No estimate of the apoB lipoprotein-related risk of CVD is complete without measurement of both apoB and Lp(a) ApoB is the true core marker of atherogenic particle burden, and Lp(a) is an independent, non-negotiable player in cardiovascular risk. ✅ ApoB reflects the number of atherogenic particles, not just the cholesterol they carry. ✅ Lp(a) adds risk beyond ApoB—even in normolipidemic patients. ✅ The combination of both offers superior prediction of events and treatment guidance. 👉 It's time to stop counting cholesterol and start counting particles. If your risk assessment doesn’t include ApoB and Lp(a), you’re not seeing the full picture. Let’s raise the bar in preventive cardiology. doi.org/10.1093/eurheartj/eh… @society_eas @fhpatienteurope @escardio @ehj_ed
13
92
5
300
22,832
Carlos Fernandez, PharmD retweeted
ICYMI: The ACC recently launched a comprehensive resource package, "HF in a Box," designed to support clinicians in the management of #HeartFailure. All resources address HF GDMT & are available free of charge in both English & Spanish. Find out more: bit.ly/3SotOXR
5
16
47
6,210
Carlos Fernandez, PharmD retweeted
This is a very good review of type 2 diabetes jamanetwork.com/journals/jam…
2
99
1
429
34,330
How low can you go…😉
📢 Hot off the press in @LipidJournal: LDL-C management just got clearer: “Lower for longer is better.” This new guidance from the National Lipid Association brings no-nonsense, risk-based recommendations for real-world practice. ✅ LDL-C is causal ✅ Lowering it reduces events ✅ Targets can go <40 mg/dL safely ✅ Time matters—start early, stay low 📉 Don’t wait for plaque to build up—treat the cause, not the consequence. 👉 Read it here: lipidjournal.com/article/S19… @CBallantyneMD @nationallipid @Drlipid
69
Break down key updates from the @nkf’s 2025 Spring Clinical Meetings—now streaming on @medliveofficial. This free, #CME-credited program offers practical insights into diagnosing and managing two rare forms of #KidneyDisease: C3 glomerulopathy (#C3G) and primary immune complex membranoproliferative glomerulonephritis (#ICMPGN): bit.ly/42RjfB9 #Nephrology #C3Glomerulopathy #Glomerulopathy #Glomerulonephritis #Kidney #MPGN #MedicalEducation #NKFClinicals @goKDIGO
1
2
4
1,480
SGLT2i can reduce the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. Read more in #EHJ 👉 bit.ly/4eMWqTe @RoccoMontone @ehj_ed #diabetes
1
50
3
162
17,218
Replying to @CBallantyneMD
@CBallantyneMD’s interest in preventive cardiology was inspired by his family’s history of heart disease. He knows that early interventions—like controlling LDL-C levels—can reduce the burden of cardiovascular disease and save lives. bit.ly/4gF9s7u
1
1
7
6,628
#Betablockers in #HFpEF: no evidence to support use, some evidence of undesirable effects Do you deprescribe #BBlockers in pts w #HFpEF, particularly given prevalence / burden of #chronotropicIncompetence? Could there be a role for #pacing HFpEF? #HFpEFBridgingDisciplines
4
11
1
46
4,883
Central limit theorem If the sample size is sufficiently large then the sampling distribution of the mean approximates a normal distribution, even if the underlying distribution from which the samples were drawn was not normal. 🔗associationofanaesthetists-p…
3
7
1,567
Carlos Fernandez, PharmD retweeted
V. interesting paper suggests statins cost effective for essentially all adults Given this work & recent results from @arjunmanrai @JamesADiao on issues w/ PREVENT vs PCE risk functions, is it time to move beyond risk-centric paradigm for statin allocation?
10
20
2
71
16,258
Carlos Fernandez, PharmD retweeted
Early intensive lipid lowering therapy saves lives ❤️ 💊 💉 🔸 Strike while the iron is hot (immediately post event) 🔹 Follow patients up & communicate LDL goals to patient & primary care 🔸 Listen to concerns & educate the patient on the ‘legacy affect’ of LDL lowering LDL⤵️, earlier, longer 👉🏼 better outcomes @RACGP #MedTwitter #CardioTwitter #MedEd #FOAMed
3
15
1
44
4,146
Always love a good review… it’s like my homework is already mostly done ✔️
Super review on mineralocorticoid receptor antagonists and the evidence to support their use in #heartfailure across the #LVEF continuum @AndrewJSauer jacc.org/doi/10.1016/j.jchf.… #MRA #steroidalMRA #nonsteroidalMRA
1
236
Carlos Fernandez, PharmD retweeted
you can reverse heart disease and stabilise plaques
#PCSK9i plus high-intensity statin therapy achieves 2% plaque burden regression at vessel level 5% PB regression at LESION level 10% PB regression at the most narrow (MLA) vessel spot Just published @JAMACardio @FBiccire jamanetwork.com/journals/jam…
3
8
17
2,241
Carlos Fernandez, PharmD retweeted
Just published systematic review found moderate certainty evidence that monitoring oncology patients’ status by asking them to complete patient-reported outcome measurement instruments reduces mortality and improves quality of life. Remarkable! pubmed.ncbi.nlm.nih.gov/3913…
3
14
50
3,157
Carlos Fernandez, PharmD retweeted
Here is an incredible article about LDL-C exposure over time and so sad it is firewalled for $40. Anyone advising patients about apoB or LDL-C should get this from their hospital library. @nationallipid @society_eas @society_eas @escardio #cholesterol nature.com/articles/s41569-0…
9
31
3
166
19,003
Carlos Fernandez, PharmD retweeted
See Carriazo S, et al Clin Kidney J 2020; 13:504-509 for details of the argument that hypertension is an uncommon cause of CKD. The “< 5% “ is an estimate of how “uncommon” based on frequency of low nephron endowement, APOL1 nephropathy, genetic KD and GN in the population.
1
20
1,896
Carlos Fernandez, PharmD retweeted
🔥 A new therapeutic era in #HFpEF #FINEARTSHF with definitive evidence supporting the role of the non-steroidal MRA finerenone at #ESCCongress Now in @NEJM nejm.org/doi/full/10.1056/NE…
18
179
5
482
51,443
Carlos Fernandez, PharmD retweeted
It takes >3-4 weeks of steroids (@ any dose >5 mg pred/d) to pose risk of adrenal insufficiency – Hence, Endocrine Society Guideline says short-term glucocorticoid therapy of <3-4 wks, irrespective of dose, DOES NOT require GC tapering buff.ly/4gggMq6
8
294
11
802
80,742